Author: Ogata, A. F.; Maley, A. M.; Wu, C.; Gilboa, T.; Norman, M.; Lazarovits, R.; Mao, C.-P.; Newton, G.; Chang, M.; Nguyen, K.; Kamkaew, M.; Zhu, Q.; Gibson, T. E.; Ryan, E.; Charles, R.; Marasco, W. A.; Walt, D. R.
Title: Serial Profiling of SARS-CoV-2 Antigens and Antibodies in COVID-19 Patient Plasma Cord-id: wd7drbky Document date: 2020_7_26
ID: wd7drbky
Snippet: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide. PCR tests are currently the gold standard for diagnosis of the current coronavirus disease (COVID-19) and serology tests are used to detect seroconversion in infected patients. However, there is a lack of quantitative and ultra-sensitive viral antigen tests for COVID-19. Here we show that Single Molecule Array (Simoa) assays can quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucle
Document: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide. PCR tests are currently the gold standard for diagnosis of the current coronavirus disease (COVID-19) and serology tests are used to detect seroconversion in infected patients. However, there is a lack of quantitative and ultra-sensitive viral antigen tests for COVID-19. Here we show that Single Molecule Array (Simoa) assays can quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of COVID-19 patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we show correlation between production of antibodies and clearance of viral antigens from serial plasma samples from COVID-19 patients. Furthermore, we demonstrate the presence of viral antigens in blood correlates with disease severity in hospitalized COVID-19 patients. These data suggest that SARS-CoV-2 viral antigens in the blood could be a marker for severe COVID-19 cases.
Search related documents:
Co phrase search for related documents- active infection and longitudinal study: 1, 2, 3, 4, 5
- active infection and low concentration: 1
- active infection and lung damage: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and additional information: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and admission post day: 1, 2, 3, 4
- acute respiratory distress syndrome and admit patient: 1
- acute respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory distress syndrome and low concentration: 1
- acute respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress syndrome and lung damage patient: 1
- additional information and adequate information: 1, 2
- additional information and longitudinal study: 1, 2
- additional information and lung damage: 1
- adequate information and longitudinal study: 1
- adequate information and lung damage: 1
- lod detection and longitudinal antigen: 1
Co phrase search for related documents, hyperlinks ordered by date